Overall survival · 1088 patients with early HCC
1 finding from 1 review
2‐year survival · 1088 patients with early HCC
1 finding from 1 review
Event‐free survival · 1088 patients with early HCC
1 finding from 1 review
Overall survival · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease progression · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes proportion of people with disease progression compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether E1B‐deleted (dl1520) adenovirus changes adverse events considered non‐serious (number of participants) compared with percutaneous ethanol injection (very low certainty).
1 finding from 1 review
Intervention not reported
PEI versus PAI · hospitalised people with early HCC treated with PEI, PAI, or surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Overall survival · hospitalised people with early HCC treated with PEI, PAI, or surgery.
1 finding from 1 review
no estimate extracted
185 participants
Low
Intervention not reported
Recurrence‐free survival · hospitalised people with early HCC treated with PEI, PAI, or surgery.
1 finding from 1 review
no estimate extracted
185 participants
Low
Intervention not reported
Number and type of adverse events · hospitalised people with early HCC treated with PEI, PAI, or surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Duration of hospital stay · hospitalised people with early HCC treated with PEI, PAI, or surgery.
1 finding from 1 review
no estimate extracted
125 participants
Very low
Intervention not reported
Quality of life · hospitalised people with early HCC treated with PEI, PAI, or surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
PEI versus surgery · hospitalised people with early HCC treated with PEI, PAI, or surgery.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · high‐risk surgical patients with acute calculous cholecystitis.
It is very uncertain whether intervention changes mortality compared with control (very low certainty).
1 finding from 1 review
Serious adverse events · high‐risk surgical patients with acute calculous cholecystitis.
It is very uncertain whether intervention changes serious adverse events compared with control (very low certainty).
1 finding from 1 review